Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study

ABSTRACT: Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study

PROVIDER: PRJNA795911 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17524800_1.fastq.gz	Fastqsanger.gz
	SRR17524800_2.fastq.gz	Fastqsanger.gz
	SRR17524801_1.fastq.gz	Fastqsanger.gz
	SRR17524801_2.fastq.gz	Fastqsanger.gz
	SRR17524802_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 94

Similar Datasets

Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study

Project description:Ruxolitinib is a Janus kinase 1/2 inhibitor (JAK1/2) that blocks signal transduction of interferon-gamma, a critical cytokine involved in the pathogenesis of cutaneous lichen planus (LP). In this prospective phase II study, we investigated the efficacy of topical ruxolitinib in cutaneous LP and performed transcriptomic analysis pre- and post-therapy. Twelve patients with cutaneous LP applied topical ruxolitinib twice daily for 8 weeks. Primary endpoints were change in total lesion count and modified Composite Assessment of Index Lesion Severity (mCAILS) score in index treated and untreated index control lesions at week 4. Total lesion count decreased by a median of 50 lesions (interquartile range 25, 723; p<0.001). mCAILS scores decreased by a mean difference of 7.6 (standard deviation 8.8, p=0.016) between index treated and control lesions. Type I and II interferon pathways were enriched in LP and responsive disease displayed downregulation of interferon-stimulated genes (ISGs). In this small pilot study, topical ruxolitinib was highly effective in the treatment of cutaneous LP. Transcriptomic analysis confirmed LP as an interferon-driven disease and downregulation of ISGs correlated with disease response.

2022-01-13 | GSE193351 | GEO

Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study

Project description:Necrobiosis Lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the JAK 1/2 inhibitor, ruxolitnib, in the treatment of NL and identify biomarkers associated with disease and treatment response. We conducted an open-label, phase 2 study of ruxolitinib in 12 patients with NL. We performed transcriptomic analysis of tissue samples pre- and post-treatment. At week 12, the mean NL lesion score decreased by 58.2% (SD 28.7%, P=0.003). Transcriptomic analysis demonstrated enrichment of type I and type II interferon pathways in baseline disease. Weighted Gene Co-expression Network Analysis (WGCNA) demonstrated post-treatment changes in interferon pathways with key hub genes IFNG and STAT1. Limitations include small sample size and a study group limited to patients with <10% BSA. In conclusion, ruxolitinib is an effective treatment for NL and targets the key pathogenic mediators of disease.

2024-02-19 | GSE255518 | GEO

Transcrpitomic analysis of Oral lichen planus with immumosuppressive therapy

Project description:We compared the transcriptomes of tissues from Oral lichen planus patients with immunosuppressive therapy to reveal the biological mechanism of oral lichen planus treatment.

2022-06-05 | GSE204663 | GEO

Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study

Project description:Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study

| PRJNA1075144 | ENA

Profiling of Salivary Exosomal microRNAs in Oral Lichen Planus Patients [set 2]

Project description:In this study, we compared microRNA (miRNA) profiles of salivary exosomes of patients with oral lichen planus with those of healthy controls. Saliva samples from 16 patients with oral lichen planus and 8 healthy controls were divided into 2 sets and were examined by performing miRNA microarray analysis. Examination of 8 oral lichen planus patients and 4 healthy controls. Each patient and control represent pooled RNAs from salivary exosomes of 8 patients and 4 healthy controls, respectively. Please note that each set (i.e. set1 and set2) was analysed independently.

2015-04-30 | E-GEOD-68407 | biostudies-arrayexpress

Profiling of Salivary Exosomal microRNAs in Oral Lichen Planus Patients [set 1]

2015-04-30 | E-GEOD-68406 | biostudies-arrayexpress

Profiling of Salivary Exosomal microRNAs in Oral Lichen Planus Patients [set 2]

2015-04-30 | GSE68407 | GEO

Profiling of Salivary Exosomal microRNAs in Oral Lichen Planus Patients [set 1]

2015-04-30 | GSE68406 | GEO

Gene expression profiling of oral and genital lichen planus epithelium and normal oral and genital epithelium

Project description:Comparing gene expression in Oral and genital lichen planus with normal oral and genital epithelium trying to idenitfy differently expressed genes in lichen planus compared to normal epithelium Total RNA obtained from oral and genital lichen planus epithelium compared with normal oral and genital epithelium

2013-11-08 | E-GEOD-52130 | biostudies-arrayexpress

Gene expression profiling of oral and genital lichen planus epithelium and normal oral and genital epithelium

2013-11-08 | GSE52130 | GEO